Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260921 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain
A NA study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 180
- Enrollment target
NCT02260921: Completed NA study, sponsored by Pacira Pharmaceuticals.
NCT02260921 is a NA study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 180 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02260921, a NA study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
Study Summary
This purpose of this study is to evaluate the effectiveness and safety of the iovera° device for the temporary reduction of pain associated with knee osteoarthritis.
Primary Outcome
The WOMAC is a tri-dimensional, disease-specific, patient-reported outcome measure. It consists of 24 questions \[each question is presented in a numerical rating scale format with possible values between 0= No (best) to 10= Extreme (worst)\] with 5 questions regarding pain \[possible subscale score 0 to 50\], 2 questions regarding stiffness \[possible subscale score 0 to 20\] and 17 questions regarding function difficulty \[possible subscale score 0 to 170\]. A negative change from Baseline ind
Interventions
- DEVICE Sham Comparator
- DEVICE iovera°
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2014-10-20 |
| Est. Completion | 2016-05-31 |
| Phase | NA |
What the finished NCT02260921 record still lists
NCT02260921 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT02260921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02260921 about?
NCT02260921 is a clinical study titled "Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain". This purpose of this study is to evaluate the effectiveness and safety of the iovera° device for the temporary reduction of pain associated with knee osteoarthritis.
What is the current status of trial NCT02260921?
This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2014-10-20. Estimated completion is 2016-05-31.
What interventions are being tested in trial NCT02260921?
The interventions under investigation include: Sham Comparator (DEVICE), iovera° (DEVICE).
Who is sponsoring clinical trial NCT02260921?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02260921's enrollment target sits among peer trials
180 586th of 2000 higher than 1,397 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI